Truist Financial Begins Coverage on Centessa Pharmaceuticals (NASDAQ:CNTA)

Truist Financial started coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) in a research report issued on Monday, Marketbeat Ratings reports. The brokerage set a "buy" rating and a $30.00 price target on the stock. Truist Financial's target price would indicate a potential upside of 94.59% from the company's previous close.

A number of other brokerages also recently issued reports on CNTA. Needham & Company LLC started coverage on Centessa Pharmaceuticals in a report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price target on the stock. Chardan Capital initiated coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set a "buy" rating and a $30.00 price target for the company. Oppenheimer initiated coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set an "outperform" rating and a $6.00 price target for the company. Piper Sandler initiated coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an "overweight" rating and a $38.00 price target for the company. Finally, Guggenheim reaffirmed a "buy" rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $28.10.

Centessa Pharmaceuticals Trading Down 1.0%

Shares of NASDAQ CNTA traded down $0.15 during midday trading on Monday, hitting $15.42. The company's stock had a trading volume of 156,335 shares, compared to its average volume of 936,178. The company has a current ratio of 14.37, a quick ratio of 14.37 and a debt-to-equity ratio of 0.28. The business's 50 day moving average is $13.44 and its two-hundred day moving average is $14.43. Centessa Pharmaceuticals has a 12-month low of $9.10 and a 12-month high of $19.09. The firm has a market cap of $2.06 billion, a P/E ratio of -8.52 and a beta of 1.45.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.15. As a group, equities research analysts expect that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Insider Transactions at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $12.71, for a total value of $699,050.00. Following the completion of the transaction, the chief executive officer owned 221,017 shares in the company, valued at $2,809,126.07. The trade was a 19.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Iqbal J. Hussain sold 12,000 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $14.02, for a total value of $168,240.00. Following the sale, the general counsel owned 105,386 shares of the company's stock, valued at approximately $1,477,511.72. This trade represents a 10.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 229,742 shares of company stock worth $3,158,169 over the last quarter. Company insiders own 7.09% of the company's stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $31,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Centessa Pharmaceuticals by 15,209.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after purchasing an additional 3,194 shares during the last quarter. Osterweis Capital Management Inc. acquired a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $47,000. Barclays PLC boosted its holdings in shares of Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after purchasing an additional 4,952 shares during the last quarter. Finally, BNP Paribas Financial Markets acquired a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth approximately $162,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.